Hepatic involvement in patients with non‑Hodgkin’s lymphoma

Czech version

Authors: M. Trněný ¹; J. Šálková ¹; J. Dlouhá ¹; J. Stříteský ²
Authors‘ workplace: I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Marek Trněný, CSc. ¹; Ústav patologie 1. lékařské fakulty UK a VFN Praha, přednosta doc. MU Dr. Pavel Dundr, Ph. D. ²
Published in: Vnitř Lék 2013; 59(7): 606-611
Category:

Overview

Non ‑⁠ Hodgkin’s lymphoma (NHL) represent the most frequent hematological malignancy with frequent extranodal involvement. We have identified 79 pts (4.6%) out of 1,712 patients with NHL, who were diagnosed in our center between 1999–2010. Five cases were primary extranodal lymphomas and we have observed one primary hepatic lymphoma (0.015%). The most frequent (61.3%) NHL subtype in our cohort was diffuse large B ‑⁠ cell lymphoma. B ‑⁠ NHL formed 92.4% of all lymphomas. We have observed high number of HBsAg positive patients (10%). The whole group have poor prognostic features with high number of patients (85%) with intermediate ‑⁠ high and high risk according to international prognostic index. The patients were treated with chemotherapy in 95%, B ‑⁠ NHL patients recieved immunochemotherapy with rituximab in 77%. The median progression free survival, resp. overall survival 4.6, resp. 8.4 years in the whole group and 1.4, resp. 8.4 years in diffuse large B ‑⁠ cell lymphoma were observed with median follow-up 4.5 years. The outcome of T ‑⁠ NHL patients was significantly worse with overall survival median 1.2 vs 8.4 years (p < 0.033). The patients with B ‑⁠ NHL treated by immunochemoterapy with rituximab had significant death risk reduction (HR 0.44, p = 0.03) compared to the patients treated with chemotherapy.

Key words:
lymphoma –⁠ non‑Hodgkin’s lymphoma –⁠ hepatic impairment –⁠ extranodal impairment –⁠ immunochemotherapy –⁠ rituximab

Sources

1. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press 2008.

2. Armitage JO, Weisenburger DD. New approach to classifying non‑Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non ‑⁠ Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16 : 2780 –⁠ 2795.

3. Trneny M, Vášová I, Pytlík R et al. Distribuce podtypů non‑hodgkinského lymfomu v České republice a jejich přežití. Klin Onkol 2007; 20 : 341 –⁠ 348.

4. Gottlieb JA, Gutterman JU, McCredie KB et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 1973; 33 : 3024 –⁠ 3028.

5. McLaughlin P, Grillo ‑⁠ López AJ, Link BK et al. Rituximab chimeric anti‑CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four‑dose treatment program. J Clin Oncol 1998; 16 : 2825 –⁠ 2833.

6. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 : 579 –⁠ 586.

7. The Non ‑⁠ Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non‑Hodgkin’s lymphoma. Blood 1997; 89 : 3909 –⁠ 3918.

8. The International Non ‑⁠ Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non‑Hodgkin’s lymphoma. N Engl J Med 1993; 329 : 987 –⁠ 994.

9. Bach AG, Behrmann C, Holzhausen HJ et al. Prevalence and imaging of hepatic involvement in malignant lymphoproliferative disease. Clin Imaging 2012; 36 : 539 –⁠ 546.

10. Civardi G, Vallisa D, Berte R et al. Focal liver lesions in non‑Hodgkin’s lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection. Eur J Cancer 2002; 38 : 2382 –⁠ 2387.

11. Baumhoer D, Tzankov A, Dimhofer S et al. Patterns of liver infiltration in lymphoproliferative disease. Histopathology 2008; 53 : 81 –⁠ 90.

12. Takahashi H, Tomita N, Yokoyama M et al. Prognostic impact of extranodal involvement in diffuse large B ‑⁠ cell lymphoma in the rituximab era. Cancer 2012; 118 : 4166 –⁠ 4172.

13. Castellani R, Bonadonna G, Spinelli P et al.Sequential pathologic staging of untreated non‑Hodgkin’s lymphomas by laparoscopy and laparotomy combined with marrow biopsy. Cancer 1977; 40 : 2322 –⁠ 2328.

14. Noronha V, Shafi NQ, Obando JA et al. Primary non‑Hodgkin’s lymphoma of the liver. Crit Rev Oncol Hematol 2005; 53 : 199 –⁠ 207.

15. Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007; 60 : 1378 –⁠ 1383.

16. Maloney DG, Liles TM, Czerwinski DK et al.Phase I clinical trial using escalating single‑dose infusion of chimeric anti‑CD20 monoclonal antibody (IDEC ‑⁠ C2B8) in patients with recurrent B ‑⁠ cell lymphoma. Blood 1994; 84 : 2457 –⁠ 2466.

17. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large ‑⁠ B ‑⁠ cell lymphoma. N Engl J Med 2002; 346 : 235 –⁠ 242.

18. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first‑line treatment for advanced follicular lymphoma. Blood 2005; 105 : 1417 –⁠ 1423.

19. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377 : 42 –⁠ 51.

20. Kluin‑Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle ‑⁠ cell lymphoma. N Engl J Med 2012; 367 : 520 –⁠ 531.

21. Trneny M, Pytlik R, Belada D et al. Treatment of diffuse large B ‑⁠ Cell lymphoma with rituximab, intensive induction and high‑dose consolidation: the final analysis of the Czech Lymphoma Study Group (CLSG) R ‑⁠ MegaCHOP ‑⁠ ESHAP ‑⁠ BEAM (R ‑⁠ MEB) trial. Blood 2007; 110 : 14A.

22. Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma ‑⁠ delta T ‑⁠ cell lymphoma. Crit Rev Oncol Hematol 2012; 83 : 283 –⁠ 292.